Summit Therapeutics (SMMT) Reports Q1 Loss of 6p/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Summit Therapeutics (SMMT) SMT C1100 Fully Enrolled in Trial Phase Ib; Needham & Company Reiterates Buy
June 12, 2015 7:30 AM EDTNeedham & Company reiterates a Buy rating and $22.00 price target on Summit Therapeutics plc (NASDAQ: SMMT) as SMT C1100 pharmacokinetics and muscle biomarkers trial is now fully enrolled and dosing patients. topline data is expected in 3Q15.
Analyst Chad Messer commented, "Summit... More
